AR051921A1 - Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion - Google Patents

Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion

Info

Publication number
AR051921A1
AR051921A1 ARP050102853A ARP050102853A AR051921A1 AR 051921 A1 AR051921 A1 AR 051921A1 AR P050102853 A ARP050102853 A AR P050102853A AR P050102853 A ARP050102853 A AR P050102853A AR 051921 A1 AR051921 A1 AR 051921A1
Authority
AR
Argentina
Prior art keywords
halogen
alkyl
cycloalkyl
optionally substituted
hydrogen
Prior art date
Application number
ARP050102853A
Other languages
English (en)
Inventor
Roger Victor Bonnert
Stephen Thom
Anil Patel
Timothy Jon Luker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of AR051921A1 publication Critical patent/AR051921A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28—Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/08—Bronchodilators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/14—Antitussive agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/14—Drugs for dermatological disorders for baldness or alopecia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/18—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to carbon atoms of six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/49—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton
    • C07C255/54—Carboxylic acid nitriles having cyano groups bound to carbon atoms of six-membered aromatic rings of a carbon skeleton containing cyano groups and etherified hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
    • C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
    • C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
    • C07C311/08—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atom of at least one of the sulfonamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/16—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C317/22—Sulfones; Sulfoxides having sulfone or sulfoxide groups and singly-bound oxygen atoms bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C317/00—Sulfones; Sulfoxides
    • C07C317/26—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton
    • C07C317/32—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton
    • C07C317/34—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring
    • C07C317/36—Sulfones; Sulfoxides having sulfone or sulfoxide groups and nitrogen atoms, not being part of nitro or nitroso groups, bound to the same carbon skeleton with sulfone or sulfoxide groups bound to carbon atoms of six-membered aromatic rings of the carbon skeleton having sulfone or sulfoxide groups and amino groups bound to carbon atoms of six-membered aromatic rings being part of the same non-condensed ring or of a condensed ring system containing that ring with the nitrogen atoms of the amino groups bound to hydrogen atoms or to carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/52—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton the carbon skeleton being acyclic and saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/64—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton
    • C07C323/65—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and sulfur atoms, not being part of thio groups, bound to the same carbon skeleton containing sulfur atoms of sulfone or sulfoxide groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/26—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Diabetes (AREA)
  • Immunology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Dermatology (AREA)
  • Endocrinology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Otolaryngology (AREA)
  • AIDS & HIV (AREA)
  • Ophthalmology & Optometry (AREA)

Abstract

Reivindicacion 1: Un compuesto caracterizado porque responde a la formula (1) o una sal aceptable para uso farmacéutico del mismo, en el cual: T es un enlace, S(O)n (donde n es 0, 1 o 2), CR1R2, NR13; W es O, S(O)n (donde n es 0, 1 o 2), NR13, CR1OR2 o CR1R2; X es hidrogeno, halogeno, ciano, nitro, S(O)nR6, OR12 o C1-6 alquilo que puede ser sustituido por uno o más átomos de halogeno; Y se selecciona entre hidrogeno, halogeno, CN, nitro, SO2R3, OR4, SR4, SOR3, SO2NR4R5, CONR4R5, NR4R5, NR6SO2R3, NR6CO2R6, NR6COR3, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7 o alquilo C1-6, estando los ultimos cuatro grupos optativamente sustituidos por uno o más sustituyentes seleccionados en forma independiente entre halogeno, OR6 y NR6R7, S(O)nR6 donde n es 0, 1 o 2; Z es arilo o heteroarilo, sustituido optativamente por uno o más sustituyentes seleccionados en forma independiente entre hidrogeno, halogeno, CN, OH, SH, nitro, CO2R6, SO2R9, OR9, SR9, SOR9, SO2NR10R11, CONR10R11, NR10R11, NHSO2R9, NR9SO2R9, NR6CO2R6, NHCOR9, NR9COR9, NR6CONR4R5, NR6SO2NR4R5, arilo, heteroarilo, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7, estando los ultimos cuatro grupos optativamente sustituidos por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, OR6, NR6R7, S(O)nR6 (donde n es 0, 1 o 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; R1 y R2 representan en forma independiente un átomo de hidrogeno, halogeno, alquenilo C2-6, alquinilo C2-6, cicloalquilo C3-7 o un grupo alquilo C1-6, estando los ultimos cuatro grupos optativamente sustituidos por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, NR6R7, OR6, S(O)nR6 (donde n es 0, 1 o 2); o R1 y R2 jun tos pueden formar un anillo de 3-8 miembros que contiene optativamente uno o más átomos seleccionados entre O, S, NR6 y en sí mismo sustituido optativamente por uno o más alquilo C1-3 o halogeno; R3 representa cicloalquilo C3-7, alquilo C1-6, alquenilo C2-6 o alquinilo C2-6 todos los cuales pueden estar optativamente sustituidos por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 o 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; R4 y R5 representan en forma independiente hidrogeno, cicloalquilo C3-7 o alquilo C1-6, estando los dos ultimos grupos sustituidos optativamente por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 o 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; R4 y R5 junto con el átomo de nitrogeno al cual están unidos pueden formar un anillo heterocíclico saturado de 3-8 miembros que contiene optativamente uno o más átomos seleccionados entre O, S(O)n (donde n = 0, 1 o 2), NR8, y en sí mismo sustituido optativamente por halogeno o alquilo C1-3; R6 y R7 representan en forma independiente un átomo de hidrogeno o alquilo C1-6; R8 es hidrogeno, alquilo C1-4, -COalquiloC1-4, CO2alquiloC1-4 o CONR6alquiloC1-4; R9 representa arilo, heteroarilo, cicloalquilo C3-7 o alquilo C1-6, pudiendo los ultimos dos grupos estar sustituidos optativamente por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, arilo heteroarilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 o 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; R10 y R11 representan en forma independiente arilo o heteroarilo, hidrogeno, cicloalquilo C3-7; o alquilo C1-6, estando los dos ultimos grupos sustituidos optativamente por uno o más sustituyentes seleccionados en forma independiente entre halogeno, cicloalquilo C3-7, arilo, heteroarilo, OR6 y NR6R7, S(O)nR6 (donde n = 0, 1 o 2), CONR6R7, NR6COR7, SO2NR6R7 y NR6SO2R7; o R10 y R11 junto con el átomo de nitrogeno al cual están unidos pueden formar un anillo heterocíclico saturado de 3-8 miembros que contiene optativamente uno o más átomos seleccionados entre O, S(O)n (donde n = 0, 1 o 2), NR8, y en sí mismo sustituido optativamente por halogeno; o C1-3 alquilo; R12 representa un átomo de hidrogeno o alquilo C1-6 que puede ser sustituido por uno o más átomos de halogeno; y R13 representa un átomo de hidrogeno, alquilo C1-6 que puede ser sustituido por uno o más átomos de halogeno o cicloalquilo C3-7, SO2R6 o COalquiloC1-4, con las siguientes salvedades: cuanto T es carbono o un enlace, el sustituyente en el grupo Z no puede ser NR10R11, donde R10R11 son en forma independiente hidrogeno, arilo, o alquilo; y se excluyen los compuestos ácido 2-[(4-carboxifenil)amino]-4,5-dihidroxi-bencenpropanoico y ácido 4-cloro-2-[(4-clorofenil)tio]-bencenacético.
ARP050102853A 2004-07-08 2005-07-08 Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion AR051921A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB0415320.1A GB0415320D0 (en) 2004-07-08 2004-07-08 Novel compounds

Publications (1)

Publication Number Publication Date
AR051921A1 true AR051921A1 (es) 2007-02-21

Family

ID=32865656

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP050102853A AR051921A1 (es) 2004-07-08 2005-07-08 Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion

Country Status (11)

Country Link
US (1) US8022248B2 (es)
EP (1) EP1765768B1 (es)
JP (1) JP4869225B2 (es)
CN (2) CN101014564B (es)
AR (1) AR051921A1 (es)
ES (1) ES2442677T3 (es)
GB (1) GB0415320D0 (es)
HK (1) HK1171736A1 (es)
TW (1) TW200612892A (es)
UY (1) UY29004A1 (es)
WO (1) WO2006005909A1 (es)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE0301009D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301010D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) * 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) * 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
TW200745003A (en) 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007052023A2 (en) * 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
ATE545637T1 (de) * 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
MX2009001876A (es) 2006-08-21 2009-03-06 Array Biopharma Inc Derivados de acido fenoxifenilacetico 4-sustituidos.
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты
US8168678B2 (en) 2008-02-01 2012-05-01 Panmira Pharmaceuticals, Inc. N,N-disubstituted aminoalkylbiphenyl antagonists of prostaglandin D2 receptors
JP2011512359A (ja) 2008-02-14 2011-04-21 アミラ ファーマシューティカルズ，インク． プロスタグランジンｄ２受容体のアンタゴニストとしての環式ジアリールエーテル化合物
WO2009108720A2 (en) 2008-02-25 2009-09-03 Amira Pharmaceuticals, Inc. Antagonists of prostaglandin d2 receptors
LT2264009T (lt) * 2008-03-12 2019-04-25 Ube Industries, Ltd. Piridilaminoacto rūgšties junginys
WO2009145989A2 (en) 2008-04-02 2009-12-03 Amira Pharmaceuticals, Inc. Aminoalkylphenyl antagonists of prostaglandin d2 receptors
WO2009151910A2 (en) * 2008-05-25 2009-12-17 Wyeth Combination product of receptor tyrosine kinase inhibitor and fatty acid synthase inhibitor for treating cancer
TWI403319B (zh) 2008-07-03 2013-08-01 Panmira Pharmaceuticals Llc 前列腺素ｄ2受體之雜烷基拮抗劑
GB2463788B (en) 2008-09-29 2010-12-15 Amira Pharmaceuticals Inc Heteroaryl antagonists of prostaglandin D2 receptors
WO2010039977A2 (en) 2008-10-01 2010-04-08 Amira Pharmaceuticals, Inc. Heteroaryl antagonists of prostaglandin d2 receptors
US8524748B2 (en) 2008-10-08 2013-09-03 Panmira Pharmaceuticals, Llc Heteroalkyl biphenyl antagonists of prostaglandin D2 receptors
WO2010057118A2 (en) 2008-11-17 2010-05-20 Amira Pharmaceuticals, Inc. Heterocyclic antagonists of prostaglandin d2 receptors
JP5300033B2 (ja) 2009-03-30 2013-09-25 宇部興産株式会社 緑内障の治療又は予防のための医薬組成物
EP2461809A4 (en) 2009-07-31 2013-06-19 Panmira Pharmaceuticals Llc OPHTHALMIC PHARMACEUTICAL COMPOSITIONS OF DP2 RECEPTOR ANTAGONSITES
KR20120047273A (ko) 2009-08-05 2012-05-11 판미라 파마슈티칼스, 엘엘씨 Ｄｐ2 길항제 및 이의 용도
US20120226036A1 (en) * 2009-09-11 2012-09-06 Ube Industries, Ltd. Substituted carbonyl compound
WO2011030871A1 (ja) * 2009-09-11 2011-03-17 宇部興産株式会社 Ｎ－置換ヘテロアリール化合物
CA2782085A1 (en) * 2010-01-06 2011-07-14 Panmira Pharmaceuticals, Llc Dp2 antagonist and uses thereof
WO2012004722A1 (en) 2010-07-05 2012-01-12 Actelion Pharmaceuticals Ltd 1-phenyl-substituted heterocyclyl derivatives and their use as prostaglandin d2 receptor modulators
EP2457900A1 (en) 2010-11-25 2012-05-30 Almirall, S.A. New pyrazole derivatives having CRTh2 antagonistic behaviour
EP2526945A1 (en) 2011-05-25 2012-11-28 Almirall, S.A. New CRTH2 Antagonists
EP2548863A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists.
EP2548876A1 (en) 2011-07-18 2013-01-23 Almirall, S.A. New CRTh2 antagonists
MX2014007239A (es) 2011-12-16 2014-08-08 Atopix Therapeutics Ltd Combinacion de un antagonista crth2 y un inhibidor de bomba de proton para el tratamiento de esofagitis eosinofilica.
RU2014129613A (ru) 2011-12-21 2016-02-10 Актелион Фармасьютиклз Лтд Гетероциклильные производные и их применение в качестве модуляторов рецептора простагландина d2
CN104428305A (zh) 2012-07-05 2015-03-18 埃科特莱茵药品有限公司 1-苯基-取代的杂环衍生物及其作为前列腺素d2受体调节剂的用途

Family Cites Families (90)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB690816A (en) 1950-01-02 1953-04-29 British Drug Houses Ltd Improvements in or relating to the manufacture of substituted phenoxy acetic acids
US3278524A (en) * 1962-03-13 1966-10-11 Beecham Group Ltd Penicillins and their production
CH432119A (de) 1963-02-22 1967-03-15 Geigy Ag J R Verwendung von Halogen-o-hydroxy-diphenyläthern als antimikrobielle Mittel
US3673243A (en) * 1968-05-08 1972-06-27 Sumitomo Chemical Co Novel process for producing o-anilinophenylaliphatic acid derivatives
BE754532A (fr) * 1969-08-07 1971-02-08 Rhone Poulenc Sa Nouveaux derives de la dibenzazepine et leur preparation
BE790679A (fr) 1971-11-03 1973-04-27 Ici Ltd Derives de l'indole
US3954764A (en) * 1973-03-30 1976-05-04 Hoffmann-La Roche Inc. Dibenzo [b,f]thiepins bearing piperazinyl substitution
DE2412520C2 (de) * 1973-03-30 1982-09-16 F. Hoffmann-La Roche & Co. AG, 4002 Basel Tricyclische Verbindungen, Verfahren zu deren Herstellung und diese enthaltende Präparate
DD113545A5 (es) * 1973-03-30 1975-06-12
JPS5239888B2 (es) * 1973-05-28 1977-10-07
SE419538B (sv) * 1973-10-29 1981-08-10 Eisai Co Ltd Analogiforfaranden for framstellning av 2-(n-fenoxfenyl)-propionsyraderivat
CH582476A5 (es) 1973-10-29 1976-12-15 Ciba Geigy Ag
FI753625A (es) * 1975-01-06 1976-07-07 Spofa Vereinigte Pharma Werke
GB1585963A (en) 1976-10-14 1981-03-11 Lilly Industries Ltd Aryl sulphur compounds
US4248618A (en) * 1977-05-06 1981-02-03 Ici Australia Limited Derivatives of (pyrimidyloxy)phenoxy-alkanecarboxylic acid and herbicidal compositions thereof
CS196893B1 (en) * 1977-12-22 1980-04-30 Miroslav Protiva 3-fluor-10-piperazino-8-substituted 10,11-dihydro-dibenzothiepines
FR2428629A1 (fr) 1978-06-14 1980-01-11 Hexachimie Nouveaux composes bis(aryloxycarboxyliques), leur preparation et leur utilisation en therapeutique
JPS5951943B2 (ja) 1978-08-21 1984-12-17 キツセイ薬品工業株式会社 新規なイミダゾ−ル誘導体
GB2041363B (en) 1979-01-19 1982-10-06 Pfizer Ltd N-benzyl-imidazoles
US4670566A (en) * 1979-07-12 1987-06-02 A. H. Robins Company, Incorporated 3-methyl-hio-4-(5-, 6-, or 7-)phenylindolindolin-2-ones
US4486593A (en) 1983-01-19 1984-12-04 The Upjohn Company 2-,3-, or 4-Pyridinylmethylamino arylic acids as thromboxane A2 synthetase and 5-lipoxygenase inhibitors
JPS62198616A (ja) * 1986-02-24 1987-09-02 Res Dev Corp Of Japan 脳血流量改善・脳細胞保護剤
US5006542A (en) * 1988-10-31 1991-04-09 E. R. Squibb & Sons, Inc. Arylthioalkylphenyl carboxylic acids, derivatives thereof, compositions containing same and method of use
US5145790A (en) 1990-05-04 1992-09-08 Abbott Laboratories Reagents and method for detecting polychlorinated biphenyls
JPH0429980A (ja) * 1990-05-25 1992-01-31 Hokko Chem Ind Co Ltd アリールプロピオン酸誘導体および除草剤
EP0540165A1 (en) 1991-10-03 1993-05-05 Zeneca Limited Alkanoic acid derivatives
US5827868A (en) * 1991-10-07 1998-10-27 E. R. Squibb & Sons, Inc. Prostaglandin analogs
WO1993012086A1 (en) 1991-12-11 1993-06-24 Ss Pharmaceutical Co., Ltd. Arylamide derivative
CA2090283A1 (en) * 1992-02-28 1993-08-29 Nobuyuki Hamanaka Phenoxyacetic acid derivatives
ES2156120T3 (es) * 1992-12-08 2001-06-16 Ss Pharmaceutical Co Derivados arilamidicos.
JPH06313995A (ja) 1993-04-28 1994-11-08 Hodogaya Chem Co Ltd 静電荷像現像用トナー
EP0622816B1 (en) 1993-04-30 1998-07-22 Kabushiki Kaisha Meidensha Electrode and process for forming an electrode material
JPH07140725A (ja) 1993-06-25 1995-06-02 Hodogaya Chem Co Ltd 負帯電性トナー用摩擦帯電付与部材
JPH07233153A (ja) * 1994-02-18 1995-09-05 Dainippon Pharmaceut Co Ltd ７位が置換された１−（２−ヒドロキシフェニル）−２（１ｈ）−キノキサリノン誘導体
WO1997008126A1 (en) 1995-08-28 1997-03-06 American Home Products Corporation Phenoxy acetic acids as aldose reductase inhibitors and antihyperglycemic agents
FR2743366B1 (fr) * 1996-01-10 1998-02-06 Rhone Poulenc Rorer Sa Derives de 5h,10h-imidazo(1,2-a)indeno(1,2-e)pyrazine-4-one, leur preparation, leurs intermediaires et les medicaments les contenant
DK0939628T3 (da) 1996-07-22 2003-07-07 Monsanto Co Thiolsulfon-metalloproteaseinhibitorer
EP0839808A1 (en) 1996-10-29 1998-05-06 Novartis AG Pyrazole derivatives, processes for their preparation, and their use as herbicides
FR2763588B1 (fr) * 1997-05-23 1999-07-09 Cird Galderma Composes triaromatiques, compositions les contenant et utilisations
GB9714249D0 (en) 1997-07-08 1997-09-10 Angiogene Pharm Ltd Vascular damaging agents
CO4960662A1 (es) 1997-08-28 2000-09-25 Novartis Ag Ciertos acidos 5-alquil-2-arilaminofenilaceticos y sus derivados
US5942532A (en) 1997-09-05 1999-08-24 Ortho Pharmaceutical Corporation 2-substituted phenyl-benzimidazole antibacterial agents
ES2226167T3 (es) 1997-09-12 2005-03-16 MERCK FROSST CANADA & CO. Piridinas 2,3,5-sustituidas como inhibidores de ciclooxigenasa 2.
AU735737B2 (en) * 1997-10-14 2001-07-12 Asahi Kasei Kabushiki Kaisha Biphenyl-5-alkanoic acid derivatives and use thereof
JP2002506851A (ja) * 1998-03-13 2002-03-05 メルク フロスト カナダ アンド カンパニー カルボン酸類およびアシルスルホンアミド類、そのような化合物を含む組成物ならびに治療方法
CZ290693B6 (cs) * 1998-06-19 2002-09-11 Vúfb, A. S. Deriváty hydroxyfenylmerkaptobenzoových a hydroxyfenylmerkaptoaryloctových kyselin s antileukotrienovou aktivitou
GB9900334D0 (en) 1999-01-07 1999-02-24 Angiogene Pharm Ltd Tricylic vascular damaging agents
GB9900752D0 (en) 1999-01-15 1999-03-03 Angiogene Pharm Ltd Benzimidazole vascular damaging agents
HUP0201203A3 (en) * 1999-06-03 2004-12-28 Nippon Suisan Kaisha Ltd Tricyclic fused heterocycle compounds, process for preparing the same and use thereof and pharmaceutical compositions containing the compounds
AU772121B2 (en) 1999-08-23 2004-04-08 Bml, Inc. Method of identifying properties of substance to prostaglandin D receptors
US6417212B1 (en) 1999-08-27 2002-07-09 Eli Lilly & Company Modulators of peroxisome proliferator activated receptors
JP2003523336A (ja) 2000-02-18 2003-08-05 メルク エンド カムパニー インコーポレーテッド 糖尿病及び脂質障害のためのアリールオキシ酢酸
WO2003022814A1 (fr) 2001-09-07 2003-03-20 Ono Pharmaceutical Co., Ltd. Derives d'indole
JP2003531194A (ja) 2000-04-24 2003-10-21 メルク フロスト カナダ アンド カンパニー プロスタグランジンｅ阻害薬としてフェニルおよびビアリール誘導体を用いる治療方法および該方法に有用な化合物
MXPA02011770A (es) 2000-05-31 2003-04-10 Astrazeneca Ab Derivados de indol con actividad de dano vascular.
PL365694A1 (en) * 2000-06-28 2005-01-10 Teva Pharmaceutical Industries Ltd. Carvedilol
IL153484A0 (en) 2000-07-07 2003-07-06 Angiogene Pharm Ltd Colchinol derivatives as angiogenesis inhibitors
US6878522B2 (en) 2000-07-07 2005-04-12 Baiyong Li Methods for the identification of compounds useful for the treatment of disease states mediated by prostaglandin D2
WO2002008213A1 (en) 2000-07-07 2002-01-31 Angiogene Pharmaceuticals Limited Colchinol derivatives as angiogenesis inhibitors
US20040097555A1 (en) * 2000-12-26 2004-05-20 Shinegori Ohkawa Concomitant drugs
BR0210391A (pt) * 2001-06-12 2004-06-15 Elan Pharm Inc Composto, métodos de tratar um paciente que tenha ou de prevenir um paciente de contrair uma doença ou condição e de preparar um composto, e, uso de um composto
EP1501826B1 (en) 2002-02-01 2006-09-27 F. Hoffman-la Roche AG Substituted indoles as alpha-1 agonists
SE0200411D0 (sv) 2002-02-05 2002-02-05 Astrazeneca Ab Novel use
AU2003211427A1 (en) 2002-02-18 2003-09-04 Ishihara Sangyo Kaisha, Ltd. Pyridine derivatives or salts thereof and cytokine production inhibitors containing the same
NZ535603A (en) * 2002-03-20 2007-10-26 Metabolex Inc Substituted phenylacetic acids
WO2003097042A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Antagoniste de recepteur de pdg2
WO2003097598A1 (fr) 2002-05-16 2003-11-27 Shionogi & Co., Ltd. Composé comprenant un antagonisme du récepteur de pdg2
SE0201635D0 (sv) 2002-05-30 2002-05-30 Astrazeneca Ab Novel compounds
SE0202241D0 (sv) 2002-07-17 2002-07-17 Astrazeneca Ab Novel Compounds
AR042206A1 (es) * 2002-11-26 2005-06-15 Novartis Ag Acidos fenilaceticos y derivados
ES2401079T3 (es) * 2002-12-20 2013-04-16 Amgen Inc. Moduladores del asma y de la inflamación alérgica
EP1611105A1 (en) 2003-03-28 2006-01-04 Eli Lilly And Company Isoquinoline-5-sulfonic acid amides as inhibitors of akt (protein kinase b)
SE0301010D0 (sv) * 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
SE0301009D0 (sv) 2003-04-07 2003-04-07 Astrazeneca Ab Novel compounds
DE60303238T2 (de) 2003-04-25 2006-09-14 Actimis Pharmaceuticals, Inc., La Jolla Pyrimidin-Essigsäure Derivate geeignet zur Behandlung von CRTH2-bedingten Krankheiten
SA04250253B1 (ar) 2003-08-21 2009-11-10 استرازينيكا ايه بي احماض فينوكسي اسيتيك مستبدلة باعتبارها مركبات صيدلانية لعلاج الامراض التنفسية مثل الربو ومرض الانسداد الرئوي المزمن
GB0324763D0 (en) 2003-10-23 2003-11-26 Oxagen Ltd Use of compounds in therapy
US7166738B2 (en) * 2004-04-23 2007-01-23 Roche Palo Alto Llc Non-nucleoside reverse transcriptase inhibitors
GB0409921D0 (en) 2004-05-04 2004-06-09 Novartis Ag Organic compounds
WO2005115382A1 (en) 2004-05-29 2005-12-08 7Tm Pharma A/S Crth2 receptor ligands for medicinal uses
GB0415320D0 (en) 2004-07-08 2004-08-11 Astrazeneca Ab Novel compounds
GB0418830D0 (en) 2004-08-24 2004-09-22 Astrazeneca Ab Novel compounds
GB0422057D0 (en) 2004-10-05 2004-11-03 Astrazeneca Ab Novel compounds
ATE517085T1 (de) 2004-11-23 2011-08-15 Astrazeneca Ab Zur behandlung von atemwegserkrankungen geeignete phenoxyessigsäurederivate
GB0510584D0 (en) 2005-05-24 2005-06-29 Novartis Ag Organic compounds
TW200745003A (en) * 2005-10-06 2007-12-16 Astrazeneca Ab Novel compounds
JP5155171B2 (ja) 2005-10-06 2013-02-27 アストラゼネカ・アクチエボラーグ 新規化合物
WO2007052023A2 (en) 2005-11-05 2007-05-10 Astrazeneca Ab Novel compounds
ATE545637T1 (de) 2005-12-15 2012-03-15 Astrazeneca Ab Substituierte diphenylether, -amine, -sulfide und methane zur behandlung von atemwegserkrankungen
UA100983C2 (ru) * 2007-07-05 2013-02-25 Астразенека Аб Бифенилоксипропановая кислота как модулятор crth2 и интермедиаты

Also Published As

Publication number Publication date
EP1765768A1 (en) 2007-03-28
US8022248B2 (en) 2011-09-20
US20080114002A1 (en) 2008-05-15
EP1765768B1 (en) 2013-11-06
WO2006005909A1 (en) 2006-01-19
ES2442677T3 (es) 2014-02-12
HK1171736A1 (en) 2013-04-05
JP4869225B2 (ja) 2012-02-08
CN101014564B (zh) 2012-05-09
CN102557971B (zh) 2015-06-17
CN101014564A (zh) 2007-08-08
GB0415320D0 (en) 2004-08-11
UY29004A1 (es) 2006-02-24
CN102557971A (zh) 2012-07-11
TW200612892A (en) 2006-05-01
JP2008505874A (ja) 2008-02-28

Similar Documents

Publication Publication Date Title
AR051921A1 (es) Acidos sustituidos utiles como compuestos farmaceuticos para tratar trastornos respiratorios, composiciones farmaceuticas que los contienen, y procesos para su preparacion
AR045470A1 (es) Derivados de acido fenoxiacetico
ES2525763T3 (es) Derivados del ácido fenilalcanoico sustituido y sus usos para el tratamiento de enfermedades respiratorias
AR050430A1 (es) Analogos de dipeptidos inhibidores de la hepatitis c
AR051966A1 (es) Derivados de acido fenoxiacetico utiles para el tratamiento de enfermedades respiratorias
AR061737A1 (es) Compuestos derivados de pirimidina, un peoceso para su preparacion y composiciones farmaceuticas que los contienen
AR058388A1 (es) DERIVADOS DE COMPUESTOS AROMATICOS SUSTITUIDOS uTILES PARA TRASTORNOS RESPIRATORIOS , COMPOSICIONES FARMACÉUTICAS Y PROCESOS PARA SU PREPARACIoN
AR054280A1 (es) Derivados de carboxamidas y su empleo en procedimientos de lucha contra enfermedades de plantas y contra hongos nocivos
AR077267A1 (es) Derivados nitrogenados heterociclicos inhibidores selectivos de pi3k, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de enfermedades inflamatorias y/o autoinmunes.
AR048789A1 (es) Derivados de oxazol y sus composiciones como moduladores de receptor activado de proliferador de peroxisoma (ppar)
AR067663A1 (es) Derivados heterociclicos de etiloxi amidas, composiciones que los comprenden y usos de los mismos en agricultura u horticultura, como agentes antifungicos.
AR086100A1 (es) Compuestos de cromenona y composiciones farmaceuticas que los contienen
PE20161066A1 (es) Derivados de piperidinil-indol como inhibidores del factor de complemento b y usos de los mismos
AR049399A1 (es) Difenilimidazopirimidina e -imidazol aminas como inhibidores de b-secretasa y metodo de obtencion de los mismos
AR058546A1 (es) Derivados de 2- adamantilurea como inhibidores selectivos de 11 beta - hsd1
PE20141674A1 (es) Derivados de heterociclos biciclicos para el tratamiento de la hipertension arterial pulmonar
AR048641A1 (es) Compuestos de aril- o heteroarilamida ortosustituidos utiles como antago-nistas del receptor de prostaglandinas e2; composiciones farmaceuticas que los contienen y su uso en la fabricacion de un medicame
AR060875A1 (es) Derivados de 2-piridona como inhibidores de la neutrofilo elastasa humana
AR061603A1 (es) Derivados de etenilcarboxamidas microbicidas
AR078201A1 (es) Compuestos de 2-piridona y su uso en el tratamiento de enfermedades mediadas por la elastasa de neutrofilos
AR062409A1 (es) Compuesto y composicion farmaceutica, utiles como agentes terapeuticos en el tratamiento, prevencion o mejoramiento de enfermedad o trastorno caracterizado por depositos o niveles de b-amiloide elevados o para inhibir o elucidar la enzima b-secretasa, y proceso para la preparacion del compuesto
AR061371A1 (es) Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas.
ATE431345T1 (de) Als modulatoren von dopamin-d3-rezeptoren geeignete azabicyclo-(3,1,0)-hexan-derivate
AR063454A1 (es) Derivados acetamida de diazepan como inhibidores selectivos de 11 beta - hsd1. procesos de obtencion y composiciones farmaceuticas.
AR065811A1 (es) Derivados de 2-amino-4h-imidazol-4-ona,composiciones farmaceuticas que los contienen y usos para el tratamiento de la enfermedad de alzheimer y otros trastornos neurodegenerativos.

Legal Events

Date Code Title Description
FB Suspension of granting procedure